eb613
eb613: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Entera Bio Ltd. (ENTX) | Phase 3 |
FDA Decisions
FDA_MeetingFDA agreed that the NDA for EB613 would be supported by a single 24-month phase 3 study using total hip BMD as the primary endpoint.(ENTX)
Frequently asked questions
Who is developing eb613?
eb613 is being developed by Entera Bio Ltd..
What is eb613's latest FDA decision?
The most recent tracked FDA decision for eb613 is FDA_Meeting for FDA agreed that the NDA for EB613 would be supported by a single 24-month phase 3 study using total hip BMD as the primary endpoint., dated July 28, 2025.
Get deeper analysis on eb613
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis